<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362517</url>
  </required_header>
  <id_info>
    <org_study_id>QVX-V-C001</org_study_id>
    <nct_id>NCT01362517</nct_id>
  </id_info>
  <brief_title>Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B</brief_title>
  <official_title>Assessment of the Immunogenicity and Safety of Quinvaxem Vaccine (DTwP-HepB-Hib) Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by H. Influenzae Among Healthy Vietnamese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the immunogenicity and safety of the Quinvaxem vaccine
      (a liquid combination vaccine against diphtheria, tetanus, B. pertussis, hepatitis B and H.
      influenzae Type B). Healthy Vietnamese infants received three doses of vaccine at 2, 3 and 4
      months of age according to the local Expanded Programme on Immunisation (EPI) schedule
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component</measure>
    <time_frame>at 5 months (equivalent to 1 month after the third vaccination)</time_frame>
    <description>Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component</measure>
    <time_frame>at 14 months (equivalent to 12 months after the first vaccination</time_frame>
    <description>Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse and Serious Adverse Events</measure>
    <time_frame>From Day 1 up to 30 days after the third vaccination</time_frame>
    <description>Assessment of the proportion of children with adverse events and/or serious adverse events following each Quinvaxem vaccine injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Hepatitis B</condition>
  <condition>Haemophilus Influenzae Infections</condition>
  <arm_group>
    <arm_group_label>Quinvaxem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quinvaxem</intervention_name>
    <description>A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at 2, 3 and 4 months of age</description>
    <arm_group_label>Quinvaxem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants are at age of DTP vaccination of the local EPI program (60-120 days old) and
             free from any obvious health problems

          -  Have a normal gestational age (â‰¥ 37 weeks); birth weight &gt; 2.5 kg

          -  There is no congenital disease detected through interview and clinical examination

          -  Already had or not yet received Hepatitis B vaccination at birth

          -  Do not have dermatological diseases such as eczema, allergies

          -  Parent or legal guardian voluntarily provides consent for their child for
             participation in the study by signing the informed consent and agrees to comply with
             all study procedures

        Exclusion Criteria:

          -  Already vaccinated with DTP vaccine

          -  Have an acute infection at the time of study vaccination

          -  Contraindications to Quinvaxem

          -  Receiving treatment with systemic corticosteroids

          -  Currently participating in another clinical trial

          -  In receipt of a parenteral immunoglobulin preparation and/or blood/blood products
             since birth

          -  Parents intend to move to another location during the study (the next 12 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>120 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tran Ngoc Huu, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pasteur Institute of Ho Chi Minh City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pasteur Institute</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2011</study_first_posted>
  <results_first_submitted>March 27, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2013</results_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>
  <keyword>Virus</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Haemophilus Influenzae</keyword>
  <keyword>Immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at one center in Vietnam First subject first visit (FSFV): April 2010 Last subject last visit (LSLV): April 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Quinvaxem</title>
          <description>Quinvaxem : A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at 2, 3 and 4 months of age</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quinvaxem</title>
          <description>Quinvaxem : A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at 2, 3 and 4 months of age</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component</title>
        <description>Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)</description>
        <time_frame>at 5 months (equivalent to 1 month after the third vaccination)</time_frame>
        <population>Analysis population excludes one subject excluded as a protocol violator</population>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component</title>
          <description>Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)</description>
          <population>Analysis population excludes one subject excluded as a protocol violator</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of subjects with anti-diphtheria &gt;=0.1 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="87.3" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-pertussis &gt;=20 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-tetanus &gt;=0.1 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="94.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-hepatitis B &gt;=10 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="87.3" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-PRP&gt;=0.15 mcg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component</title>
        <description>Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)</description>
        <time_frame>at 14 months (equivalent to 12 months after the first vaccination</time_frame>
        <population>Analysis population excludes one subject excluded as a protocol violator and additionally at 14 months one lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component</title>
          <description>Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)</description>
          <population>Analysis population excludes one subject excluded as a protocol violator and additionally at 14 months one lost to follow up</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of subjects with anti-diphtheria &gt;=0.1 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" lower_limit="81.5" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-pertussis &gt;=20 EU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" lower_limit="40.7" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-tetanus &gt;=0.1 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="74.5" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-hepatitis B &gt;=10 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" lower_limit="68.5" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of subjects with anti-PRP &gt;=0.15 mcg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="93.4" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Adverse and Serious Adverse Events</title>
        <description>Assessment of the proportion of children with adverse events and/or serious adverse events following each Quinvaxem vaccine injection</description>
        <time_frame>From Day 1 up to 30 days after the third vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
            <description>Quinvaxem : A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at 2, 3 and 4 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Adverse and Serious Adverse Events</title>
          <description>Assessment of the proportion of children with adverse events and/or serious adverse events following each Quinvaxem vaccine injection</description>
          <units>Number of children with AE per 100 doses</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Doses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;=38 deg C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Parents of subjects recorded solicited local and systemic and unsolicited adverse events from baseline up to 28 days after vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>First Dose</title>
          <description>Quinvaxem : A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose given at 2 months of age</description>
        </group>
        <group group_id="E2">
          <title>Second Dose</title>
          <description>Quinvaxem : A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose given at 3 months of age</description>
        </group>
        <group group_id="E3">
          <title>Third Dose</title>
          <description>Quinvaxem : A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose given at 4 months of age</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pulmonary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="131"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="131"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Persistent crying</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Feeding disorder</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="131"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator to submit all manuscripts/abstracts to the sponsor for review at least 60 days prior to any intended submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Director</name_or_title>
      <organization>Crucell Switzerland AG</organization>
      <phone>+41(0)319806111</phone>
      <email>info@crucell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

